The convergence of biology and chemistry has shaped current drug discovery and development, bridging the gap between biological processes and chemical interventions. Nowhere is this key trend more perfectly embodied today than in the burgeoning field of bioconjugation.
The field has gained significant attention due to the success of antibody-drug conjugates (ADCs). Nevertheless, the ADCs area is still nascent and brimming with the potential for further growth and technical innovation in antibody, linker, and payload components. Furthermore, the application of bioconjugation tools and techniques now stretches far beyond ADCs and other established fields such as conjugated vaccines and diagnostics.
Against this background of rapid growth in both technological innovation and applications, Bioconjugation Insights provides a unique platform for the bioconjugation community’s experts to explore key current trends, challenges, and breakthroughs. Core areas for coverage include, but are not limited to:
BioInsights’ signature blend of in-depth scientific and technical detail with ‘big picture’ strategic analysis provides the perfect platform to contextualize recent progress, address current issues, and share insight into future directions for this rapidly developing sector. Additionally, Bioconjugation Insights comprehensive scope and coverage spans engineering and design, manufacturing and supply chain, preclinical and clinical R&D, regulation, financing, market access, and more.
Bioconjugation Insights is the first and only dedicated digital content channel specifically designed to keep industry and academic professionals up to date with this truly global sector’s evolution on a genuinely worldwide scale.